Evolus has signed an exclusive U.S. licensing agreement with IBSA for Profhilo, the Italian hybrid hyaluronic-acid injectable designed for skin quality and hydration rather than volumization. The deal carries no upfront payment, suggesting Evolus is betting on royalty-based returns over time. Profhilo operates on a different mechanism than traditional HA fillers—it's a low-viscosity, high-concentration HA product that spreads and integrates into the dermis, positioning it as a complement to neuromodulators and a competitor to products like Juvéderm Hydro and Restylane Vital.
Injectables
Evolus Secures Exclusive U.S. Profhilo License From IBSA — A Skin-Quality Play to Challenge Juvéderm
No upfront payment; 15-year term positions Evolus in the hydrating-filler segment.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
No upfront payment; Evolus betting on royalty returns from a 15-year Profhilo license.
For practices, this expands Evolus' injectable portfolio beyond Jeuveau and creates another option in the crowded skin-quality space. Profhilo's clinical profile—multiple small-volume injections, 2-3 treatments per year, lower per-syringe revenue than traditional fillers—requires different patient education and pricing strategy. The 15-year term suggests Evolus sees long-term upside, but market penetration will depend on rebate aggressiveness and whether Allergan and Galderma defend their turf.
Source: original report ↗
Frequently asked questions
What is Profhilo and how does it differ from traditional dermal fillers?
Profhilo is a low-viscosity, high-concentration hyaluronic acid injectable designed for skin quality and hydration rather than volumization. Unlike traditional fillers, it spreads and integrates into the dermis through multiple small-volume injections, positioning it as a complement to neuromodulators rather than a direct volume replacement.
How often do patients need Profhilo treatments?
Profhilo typically requires 2-3 treatments per year to maintain results. The treatment protocol involves multiple small-volume injections per session, which differs significantly from the standard annual or semi-annual schedule of traditional fillers.
What does Evolus' exclusive U.S. license for Profhilo mean for medspa practices?
Evolus now has exclusive rights to distribute Profhilo in the U.S. under a 15-year agreement with IBSA, expanding its injectable portfolio beyond Jeuveau. This gives practices another option in the skin-quality segment and creates a new revenue stream, though practices will need to develop different patient education and pricing strategies compared to traditional fillers.
How does Profhilo compete with products like Juvéderm Hydro and Restylane Vital?
Profhilo operates in the same hydrating-filler segment as Juvéderm Hydro and Restylane Vital, but with a different mechanism—it's designed to integrate into the dermis for skin quality improvement rather than direct volumization. Market penetration will depend on Evolus' rebate strategy and whether Allergan and Galderma aggressively defend their existing market share.
What does the no upfront payment deal structure tell us about Evolus' confidence in Profhilo?
The royalty-based structure with no upfront payment suggests Evolus is betting on long-term market adoption and sustained revenue rather than immediate returns. This approach indicates confidence in the product's viability but also signals that Evolus is willing to take on execution risk to secure the exclusive license.
Will Profhilo generate the same revenue per syringe as traditional fillers?
No—Profhilo's clinical profile of multiple small-volume injections and 2-3 treatments per year typically generates lower per-syringe revenue than traditional volumizing fillers. Practices will need to adjust pricing strategies and patient communication to account for the different treatment frequency and mechanism of action.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.